CHMP recommends Roche ’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA)
Positive recommendation is based on interim data from ongoing RAINBOWFISH trial which showed majority ofEvrysdi-treated babies were able to stand and walk within timeframes typical of healthy babies by 12 months ’ treatment1,2If approved by the European Commission,Evrysdi will be available to treat people of all ages with SMA in the European Union, including babies from birthEvrysdi is now approved in 100 countries with more than 8,500 patients treated globallyBasel, 21 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive o...
Source: Roche Media News - July 21, 2023 Category: Pharmaceuticals Source Type: news
CHMP recommends Roche ’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA)
Positive recommendation is based on interim data from ongoing RAINBOWFISH trial which showed majority ofEvrysdi-treated babies were able to stand and walk within timeframes typical of healthy babies by 12 months ’ treatment1,2If approved by the European Commission,Evrysdi will be available to treat people of all ages with SMA in the European Union, including babies from birthEvrysdi is now approved in 100 countries with more than 8,500 patients treated globallyBasel, 21 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive o...
Source: Roche Investor Update - July 21, 2023 Category: Pharmaceuticals Source Type: news
Early MS Treatment Tied to a Reduction in Severe Disability Early MS Treatment Tied to a Reduction in Severe Disability
Initiating treatment within 6 months of the first symptoms of multiple sclerosis is linked to a 45% lower risk for disability years later.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - July 20, 2023 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Early Treatment of Demyelination Events Cuts Long-Term Disability in MS
THURSDAY, July 20, 2023 -- For multiple sclerosis patients with a first demyelinating event, earlier treatment initiation is associated with a reduction in the risk for long-term disability, according to a study published online July 19 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 20, 2023 Category: Pharmaceuticals Source Type: news
Comparison of physical performance, gait, balance, falls efficacy, and step reaction time in individuals with multiple sclerosis - Özden F, Özkeskin M, Tümtürk, Yüceyar N.
OBJECTIVE: The study aimed to investigate the physical performance, gait, balance, falls efficacy, and step reaction time in individuals with MS. METHODS: A total of 60 individuals (30 individuals with MS and 30 age and sex-matched healthy controls... (Source: SafetyLit)
Source: SafetyLit - July 19, 2023 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
Searching for a Direct Route to Multiple Sclerosis Treatment
Researchers created a new high-throughput tool to hunt for therapies that remyelinate the nervous system. (Source: The Scientist)
Source: The Scientist - July 17, 2023 Category: Science Tags: News News & Opinion Source Type: news
Retinal Thickness a New Predictor of MS Disability? Retinal Thickness a New Predictor of MS Disability?
Measuring the thickness of the retina shortly after diagnosis in multiple sclerosis patients could predict their risk of accumulated disability later in the disease course, say Austrian researchers.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - July 14, 2023 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Interferon Tumbles, Oral Agents Gain as Initial MS Treatment
(MedPage Today) -- Prescribing patterns of initial disease-modifying therapies for multiple sclerosis have shifted dramatically since 2001, with oral agents driving down the use of platform injectables 73.8% by 2020.
The inflection point occurred... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - July 13, 2023 Category: Neurology Source Type: news
What To Know About Djokovic ’s Nano Patch And Why Some Experts Call It ‘Pseudoscience’
The patch is called a TaoPatch and is produced by an Italian company that claims the device can boost athletic performance, improve diseases like multiple sclerosis and build stamina. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 13, 2023 Category: Pharmaceuticals Authors: Arianna Johnson, Forbes Staff Tags: Innovation /innovation Science /science Healthcare /healthcare Breaking breaking-news Trending Explainer Trending-Explainer topline Source Type: news
Novak Djokovic ’s Nano Patch: He Calls It His ‘Biggest Secret’—Some Experts Call It Bogus
The patch is called a TaoPatch and is produced by an Italian company that claims the device can boost athletic performance, improve diseases like multiple sclerosis and build stamina. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 13, 2023 Category: Pharmaceuticals Authors: Arianna Johnson, Forbes Staff Tags: Innovation /innovation Science /science Healthcare /healthcare Breaking breaking-news Trending Explainer Trending-Explainer topline Source Type: news
Positive Phase III results for Roche ’s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis
Phase III OCARINA II trial met primary and secondary endpointsOCREVUS twice a year, 10-minute injection has the potential to further improve the treatment experience and expand OCREVUS usage in MS centres with IV capacity limitations or without IV infrastructureOCREVUS remains the first and only therapy approved for both RMS and PPMS, and more than 300,000 people have been treated globallyBasel, 13 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III OCARINA II trial evaluating OCREVUS ® (ocrelizumab) as a twice a year 10-minute subcutaneous injection met its primary and secondary endpoints in...
Source: Roche Media News - July 13, 2023 Category: Pharmaceuticals Source Type: news
Positive Phase III results for Roche ’s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis
Phase III OCARINA II trial met primary and secondary endpointsOCREVUS twice a year, 10-minute injection has the potential to further improve the treatment experience and expand OCREVUS usage in MS centres with IV capacity limitations or without IV infrastructureOCREVUS remains the first and only therapy approved for both RMS and PPMS, and more than 300,000 people have been treated globallyBasel, 13 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III OCARINA II trial evaluating OCREVUS ® (ocrelizumab) as a twice a year 10-minute subcutaneous injection met its primary and secondary endpoints in...
Source: Roche Investor Update - July 13, 2023 Category: Pharmaceuticals Source Type: news
Stem Cell Medical Tourism Leads to Meningitis in MS Patient
(MedPage Today) -- A woman with multiple sclerosis (MS) who had intrathecal injections of umbilical cord stem cells in Mexico ended up with a severe Mycobacterium abscessus infection that took weeks to identify and treat, according to a case study... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 13, 2023 Category: American Health Source Type: news
Genes Identified in Association With Multiple Sclerosis Severity
FRIDAY, July 7, 2023 -- Authors of a study published online June 28 in Nature have identified genetic markers associated with multiple sclerosis (MS) severity.
Adil Harroud, M.D., from the University of California in San Francisco, and colleagues... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 7, 2023 Category: Pharmaceuticals Source Type: news
Factors contributing to falls in people with multiple sclerosis: the exploration of the moderation and mediation effects - Jawad A, Baattaiah BA, Alharbi MD, Chevidikunnan MF, Khan F.
The prevalence of multiple sclerosis (MS) has significantly increased in recent decades. People with MS have a high risk of falling; these falls may lead to serious injuries, affecting their quality of life PURPOSE: The aim of this study is to assess the f... (Source: SafetyLit)
Source: SafetyLit - July 3, 2023 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
